Medicine:AG0302-COVID‑19

From HandWiki
Revision as of 23:32, 4 February 2024 by LinuxGuru (talk | contribs) (over-write)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Vaccine candidate against COVID-19
AG0302-COVID‑19
Vaccine description
Target diseaseSARS-CoV-2
TypeDNA vaccination
Clinical data
Routes of
administration		Intramuscular, Intradermal[1]

AG0302-COVID‑19 is a COVID-19 vaccine candidate developed by AnGes Inc.[2][3]This candidate followed a previous one called AG0301-COVID‑19.[4]

References

  1. ↑ "Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)". United States National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT04993586. 
  2. ↑ Study of COVID-19 DNA Vaccine (AG0302-COVID19). United States National Library of Medicine. 3 December 2020. https://clinicaltrials.gov/ct2/show/NCT04527081. Retrieved 11 March 2021. 
  3. ↑ "Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)". United States National Library of Medicine. https://www.clinicaltrials.gov/ct2/show/NCT04655625. 
  4. ↑ "Study of COVID-19 DNA Vaccine (AG0301-COVID19)". United States National Library of Medicine. 9 July 2020. https://clinicaltrials.gov/ct2/show/NCT04463472. 






Retrieved from "https://handwiki.org/wiki/index.php?title=Medicine:AG0302-COVID‑19&oldid=3267615"